GlobeNewswire

ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab

Share

Regulatory progress is spurring the development of safe and effective therapies for Alzheimer’s disease

TORONTO and CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, released a white paper today that offers its perspective on aducanumab’s likelihood of regulatory approval in advance of its U.S. Food and Drug Administration Advisory Committee (AC) review on November 6. The white paper, available at www.promisneurosciences.com, chronicles aducanumab’s history, regulatory support, positive data outcomes and potential impetus for development of improved second-generation therapies. If approved, aducanumab would be the first disease-modifying treatment for Alzheimer’s disease, offering a therapeutic option for the millions of Americans living with the disease.

Aducanumab was originally designed to target amyloid-beta plaque, now believed to be an ineffective drug target for AD. An accumulating body of data has shifted the drug development focus to a different species of amyloid-beta called the toxic oligomer which has since been shown to be the real culprit in driving disease progression. Aducanumab’s ability to cross-react and partially neutralize toxic oligomers results in its modest treatment benefit. By contrast, published data show that PMN310, ProMIS’ antibody candidate for Alzheimer’s disease, is highly selective for the toxic oligomer of amyloid-beta, positioning it as a second-generation drug candidate with more precise targeting capabilities and a potentially improved safety and efficacy profile.

Despite aducanumab’s modest treatment benefit, the white paper argues that FDA approval is likely based on the following:

  1. FDA has encouraged Biogen to submit its application, granting it Priority Review; has endorsed continued clinical use of aducanumab in an open-label study, and; has demonstrated a willingness in the past to approve drugs despite limited data in instances where the unmet medical need is significant.

  2. Aducanumab’s phase 3 EMERGE trial was unequivocally positive and additional evidence for effectiveness is confirmed by results from the Phase 1b PRIME trial and subset data from the phase 3 ENGAGE trial.

  3. We anticipate the Advisory Committee members will most likely conclude that aducanumab’s data demonstrate the requisite “substantial evidence of effectiveness” and acceptable safety.

“Aducanumab represents a milestone treatment, and we applaud Biogen’s unrelenting commitment to its advancement,” said Dr. Elliot Goldstein, ProMIS Neurosciences’ President and CEO. “We and many others in the Alzheimer’s community look forward to the upcoming FDA Advisory Committee meeting and subsequent regulatory actions in support of addressing the unmet need for disease modifying therapies for Alzheimer’s disease.”

The FDA’s Advisory Committee will be virtually convened and streamed via internet on November 6, 2020.

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s disease, the DSEs are misfolded regions on toxic forms of otherwise normal proteins. In the infectious disease setting, these DSEs represent peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19. ProMIS proprietary peptide antigens can also be used to create potential therapeutic antibodies, as well as serve as the basis for development of vaccines. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn. To learn more about protein misfolding diseases, listen to Episodes 11, 24, of Saving Minds, a podcast available at iTunes or Spotify.

For media inquiries, please contact:
Shanti Skiffington
shanti.skiffington@gmail.com
Tel. 617 921-0808

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

EPH European Property Holdings Limited (EPH) - Third Quarter 2020 Financial Update25.11.2020 19:00:00 CETPress release

25 November 2020, Road Town, Tortola, BVI BUSINESS HIGHLIGHTS In Q3 2020 the Company continued to expand its activity to Europe and diversify its portfolio to ensure long-term capital preservation. Following this strategy, in July 2020, the Company acquired 100% of interest in the entity holding a hotel property in Salzgasse 4 in Dresden, Germany. The property is located in the historic centre of Dresden, very close to the main city attractions and Dresden Airport. It comprises an area of 15,550 sqm. with a total of 180 rooms, 46 underground parking spaces, a spa, restaurant, 261 sqm. of retail space and meeting rooms for up to 230 people. The property and is occupied by 4-star Hotel Innside Dresden of Melia Hotels & Resorts Group. The current lease runs till December 2029. The Company’s rental properties continue generating sufficient cash to cover the Company’s operating expenses, service the debt and partially finance its new acquisitions.The Company successfully continued sales of

REPURCHASE OF SHARES25.11.2020 18:15:00 CETPress release

REPURCHASE OF SHARES Amsterdam, the Netherlands - Flow Traders N.V. (“Flow Traders”) (Euronext: FLOW) has repurchased 53,298 of its own shares in the period from 19 November 2020 up to and including 25 November 2020 at an average price of €26.43. As announced on 11 November 2020, these repurchases are being made in order to satisfy the requirements of various employee incentive plans. The consideration of this purchase was €1.4 million. The total number of shares purchased under this programme to date is 186,430 shares at an average price of €26.66 for a total consideration of €5.0 million. 1,417,599 shares were held in treasury as at 25 November 2020. Contact Details Flow Traders N.V. Jonathan Berger / Investor Relations Officer Phone: +31 20 7996799 Email: investor.relations@flowtraders.com About Flow Traders Flow Traders is a leading global financial technology-enabled liquidity provider in financial products, historically specialized in Exchange Traded Products (ETPs), now expandin

SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING25.11.2020 16:20:00 CETPress release

Bid date, 2020-11-27Bid Submission Date2020-11-27Bid times10.30-11.00 (CET/CEST) on the Bid dateOffered Amount50 billion SEKMaximum Permitted Bid Volume12.5 billion SEK from an individual bidderSettlement Date2020-12-01Minimum Permitted Bid Volume10 million SEK per bidFinal Repayment Date2024-12-02Maximum Allocation25 per cent of Offered AmountAllocation TimeNo later than 11.30 (CET/CEST) on the Bid dateRepayment Date2021-12-01Option Repayment Date 12022-12-01Option Repayment Date 22023-12-01Interest rateThe Riksbank´s applicable repo rateAdditional interest rate0.10 per centConfirmation of bids to e-maileol@riksbank.se Stockholm, 2020-11-25 This is a translation of the special terms and conditions published on riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail.

Maha Energy AB (publ) (“Maha” or the “Company”) announce Total Depth (TD) reached on Tie South (7-TIE-2D-BA) and logging results.25.11.2020 16:00:00 CETPress release

The Company is pleased to provide the following Operational Update from its operations in Brazil. Tie-2 (Tie Field) The Tie-2 development well (7-TIE-2D-BA) reached a Total Depth of 2,195 m. on November 21. Both productive target formations were intersected. Electric logging has been completed and the well is now being prepared for production. Electric logging and drilling results confirmed the productive Agua Grande (AG) and Sergi formations are likely to be oil bearing. Indications are that both productive formations are above the Oil Water Contact and Tie-2 marks a new structural high in the Tie field with the top of its AG reservoir being 2 metres higher than the TIE-1 well (Attic well). The AG yielded 23 m. gross reservoir sand with an interpreted net productive thickness of 13 m. The Sergi yielded 17 m. gross reservoir sand with a net productive thickness of 7 m. Operations are now underway to complete the AG and Sergi formations and place 7-TIE-2D-BA on production. The informati

Klövern divests 12 properties in Malmö, Lund, Norrköping and Västerås for SEK 610 million25.11.2020 15:00:00 CETPress release

Klövern has signed contracts with Mileway to divest 12 properties for a total underlying property value of SEK 610 million. The properties, which are located in Malmö, Lund, Norrköping and Västerås, have a lettable area of approximately 120,700 sq.m. and primarily consist of warehouse/logistics premises. The rental value amounts to SEK 61 million and the economic occupancy rate amounts to 82 per cent. ”This divestment is yet another step in the streamlining of Klövern as we free up capital for other investments in our more prioritized segments”, says Peeter Kinnunen, Head of Transactions at Klövern. Transfer of possession is planned to be on 15 January 2021. The divestment encompasses the following properties: Malmö: Kullen 1, Fältsippan 8, Krukskärvan 9, Stiglädret 10 and Ventilen 4 Lund: Annedal 9, Kvartsen 6 and Trumlan 1 Norrköping: Malmen 5, Silvret 2 and Slakthuset 14 Västerås: Friledningen 18 Klövern AB (publ) For additional information, please contact: Rutger Arnhult, CEO, +46